Combinational silencing of components involved in JAK/STAT signaling pathway.

Eur J Pharm Sci

Department of Biomedical and Pharmaceutical Sciences, Center for Targeted Drug Delivery, Harry and Diane Rinker Health Science Campus, Chapman University School of Pharmacy, 9401 Jeronimo Road, Irvine, CA 92618, United States. Electronic address:

Published: August 2022

Combinatorial silencing of more than one protein via small interfering RNA (siRNA) is a new strategy that can enhance the effect of RNA interference on cell function. To explore this strategy, we selected JAK/STAT axis as a major signaling pathway that contributes to several mechanisms involved in cancer cell proliferation and survival. We focused on four proteins involved in this pathway to explore the possibility of identifying a combinatorial targeting strategy (as the proof of concept) with enhanced efficiency: gp 130 (a co-receptor for IL6 cytokines), JAK2, STAT3, and importin α3 (the nuclear transporter reportedly involved in translocation of activated STAT3 to nucleus). Selected proteins were targeted by siRNA in two selected Triple Negative Breast Cancer cell lines (MDA-MB-231 and MDA-MB-468). The effect of individual and selected combinations of siRNAs on selected downstream antiapoptotic proteins, pro-apoptosis proteins, and cell-cycle regulating proteins was explored. Combinatorial silencing of JAK2/gp 130 enhanced the effect of RNA interference on downstream proteins significantly, and demonstrated enhanced effect in reducing cell viability, cell migration, and the level of activation of STAT3. In conclusion, the promising results of simultaneous targeting of JAK2 and gp 130 might be an example for potential combinatorial silencing strategies in cancer treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2022.106233DOI Listing

Publication Analysis

Top Keywords

combinatorial silencing
12
signaling pathway
8
rna interference
8
cancer cell
8
proteins
6
cell
5
selected
5
combinational silencing
4
silencing components
4
involved
4

Similar Publications

Background: Epigenetic phytochemicals are considered as an efficacious and safe alternative to synthetic drugs in drug discovery. In this regard, combinatorial interventions enable simultaneously targeting various neoplastic pathways to eradicate multiple tumorigenic clones. Therefore, we evaluated the effects of the epigenetic-modifying compounds phenethyl isothiocyanate (PEITC) and withaferin A (WA) alone and in combination on cancer hallmarks and miRNome profiles of breast cancer (BC) cells in addition to their impact on multiple epigenetic regulatory pathways.

View Article and Find Full Text PDF

Silent silencers: Leave no trace.

Mol Cell

December 2024

School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:

The regulatory mechanisms of silencers have remained poorly understood. In this issue, Hofbauer et al. conduct a genome-wide screen in Drosophila melanogaster and reveal three silencer types that appear to work alone-without the need for combinatorial action, traditional chromatin marks, or open chromatin regions.

View Article and Find Full Text PDF

Local CpG- siRNA treatment improves antitumor effects of immune checkpoint inhibitors.

Mol Ther Nucleic Acids

December 2024

Department of Immuno-Oncology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA.

Immune checkpoint blockade (ICB) therapy has significantly benefited patients with several types of solid tumors and some lymphomas. However, many of the treated patients do not have a durable clinical response. It has been demonstrated that rescuing exhausted CD8 T cells is required for ICB-mediated antitumor effects.

View Article and Find Full Text PDF

The use of combinatorial siRNAs shows great promise for drug discovery, but the identification of safe and effective siRNA combinations remains challenging. Here, we develop a massively multiplexed technology for systematic screening of siRNA-based cocktail therapeutics. We employ composite micro-carriers that are responsive to near infrared light and magnetic field to achieve photoporation-facilitated siRNA transfection to individual cells.

View Article and Find Full Text PDF
Article Synopsis
  • Checkpoint immunotherapy struggles against non-immunogenic tumors like neuroblastoma due to low MHC class I expression and neoantigen burden, but inhibiting ERAP1 can enhance anti-tumor immune responses.
  • A novel strategy combining genetic knockout of ERAP1 with the HDAC inhibitor entinostat was developed, leading to increased immunogenicity and making neuroblastoma more responsive to PD-1 therapy.
  • Experimental methods included CRISPR/Cas9 gene editing, flow cytometry, and mass spectrometry to demonstrate that ERAP1 inhibition improves immune cell activity and increases MHC class I and PD-L1 expression in neuroblastoma cells, ultimately slowing tumor growth.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!